DMN Stock Overview
Diamyd Medical AB (publ) develops precision medicine therapies for the treatment of autoimmune diabetes.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Diamyd Medical AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr0.91 |
| 52 Week High | kr1.78 |
| 52 Week Low | kr0.54 |
| Beta | 2.07 |
| 1 Month Change | 0.44% |
| 3 Month Change | 31.69% |
| 1 Year Change | -44.35% |
| 3 Year Change | -66.57% |
| 5 Year Change | 37.48% |
| Change since IPO | 26.18% |
Recent News & Updates
Recent updates
Shareholder Returns
| DMN | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 13.3% | -0.2% | 0.5% |
| 1Y | -44.3% | -22.8% | 1.3% |
Return vs Industry: DMN underperformed the German Biotechs industry which returned -23% over the past year.
Return vs Market: DMN underperformed the German Market which returned 2.3% over the past year.
Price Volatility
| DMN volatility | |
|---|---|
| DMN Average Weekly Movement | 18.5% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: DMN's share price has been volatile over the past 3 months.
Volatility Over Time: DMN's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1984 | 26 | Ulf Hannelius | www.diamyd.com |
Diamyd Medical AB (publ) develops precision medicine therapies for the treatment of autoimmune diabetes. The company develops Diamyd, an antigen-specific immunotherapy, which is in phase III clinical trial for the treatment of type 1 diabetes and latent autoimmune diabetes in adults (LADA); and Remygen, an immunomodulation therapy, that is in phase I/II clinical trial for the treatment of with type 1 diabetes, type 2 diabetes, and LADA. It has a research and development collaboration agreement with Juvenile Diabetes Research Foundation to develop DIAGNODE-3 Phase 3 trial in type 1 diabetes.
Diamyd Medical AB (publ) Fundamentals Summary
| DMN fundamental statistics | |
|---|---|
| Market cap | €98.94m |
| Earnings (TTM) | -€10.29m |
| Revenue (TTM) | €24.15k |
4,097x
P/S Ratio-9.6x
P/E RatioIs DMN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DMN income statement (TTM) | |
|---|---|
| Revenue | kr282.00k |
| Cost of Revenue | kr3.76m |
| Gross Profit | -kr3.48m |
| Other Expenses | kr116.70m |
| Earnings | -kr120.18m |
Last Reported Earnings
Feb 29, 2024
Next Earnings Date
Jun 26, 2024
| Earnings per share (EPS) | -1.17 |
| Gross Margin | -1,234.75% |
| Net Profit Margin | -42,617.73% |
| Debt/Equity Ratio | 0% |
How did DMN perform over the long term?
See historical performance and comparison